Inactief instrument

Andere talen Jupiter Neurosciences, Inc.

Aandelen

Jupiter Neurosciences, Inc. Announces Research Breakthrough with JOTROL in Parkinson's Disease	27-02-23
Jupiter Neurosciences, Inc. Announces Appointment of New Chief Financial Officer	13-01-23
Jupiter Neurosciences, Inc. Appoints Saleem Elmasri as Chief Financial Officer	12-01-23
Jupiter Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	02-12-22
Jupiter Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16-08-22
Jupiter Neurosciences, Inc. Announces Journal of Alzheimer's Disease Publication Highlighting Use of JOTROL™	14-06-22
Jupiter Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	18-05-22
Jupiter Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	26-04-22
Jupiter Neurosciences, Inc. Auditor Raises 'Going Concern' Doubt	26-04-22
Jupiter Neurosciences, Inc. Announces Broadening of IP Estate for its Unique Resveratrol Formulation, JOTROL	01-03-22
Jupiter Neurosciences, Inc. Announces Completion of Phase I Safety Trial with Enhanced Resveratrol Product, JOTROL™	23-02-22
Jupiter Neurosciences to Issue 2.2 Million Units in IPO	27-01-22
Jupiter Neurosciences, Inc. has filed an IPO.	12-10-21
Jupiter Neurosciences, Inc. Auditor Raises 'Going Concern' Doubt	12-10-21
Jupiter Neurosciences, Inc. Announces New Corporate Offices	21-09-21

Geen resultaten voor deze zoekopdracht